Data layers Raw facts Calculated Model prediction AI interpretation

IPO Timeline Raw facts

Broker Results (T-2)
Some brokers release in afternoon
Grey Market (T-1)
Afternoon
HKEX Allotment (T-1)
Evening
Registrar Allotment (T-1)
Evening
Listing Day (T)
First day of trading

Company Overview

Stock NameJiuyuan Gene
Stock Code02566
Company Full NameTo be extracted
Industry醫療保健
Principal Activities公司是一家總部設于浙江省的中國生物制藥公司,擁有逾30年生物藥品及醫療器械研發、生產及商業化經驗。
Listing Date2024-11-28
Listing Rules EraOld Rules
Listing Rules ChapterTo be extracted
Weighted Voting Rights (WVR)No
Registered Address (Mainland China)中國浙江省杭州市錢塘區白楊街道8號大街23號
Business Address (Hong Kong)To be extracted
Place of IncorporationTo be extracted
Listing MethodTo be extracted
Listing BoardMain Board
Websitehttps://www.china-gene.com/
Share Registrar香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited)
Registrar Contact(852)2862 8628
A-Share/US Dual ListingNo data

Offering Information

Offering Mechanism To be extracted
Offer PriceHK$ 12.42 / shares
Offer Price RangeTo be extracted
Lot SizeTo be extracted
Entry ThresholdTo be extracted
Par ValueTo be extracted
Offer PeriodTo be extracted
Global Offering SharesTo be extracted
HK Public Offer Shares (Initial)To be extracted
Public Offer Lots (Initial)To be extracted
International Placing Shares (Initial)To be extracted
Offer RatioTo be extracted
Total Shares Post-IPOTo be extracted
Greenshoe (Over-allotment Option)To be confirmed
Stabilizing Manager (Greenshoe)—
Cornerstone Share49.7%
Clawback TiersTo be extracted
Reallocation OptionTo be confirmed
Total Global Offering SizeHK$ 281,926,548

Subscription Tiers

Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.

Pool A
Lots SubscribedShares SubscribedSubscription Amount (HKD)
1 lots 200 HK$ 2,484
2 lots 400 HK$ 4,968
3 lots 600 HK$ 7,452
4 lots 800 HK$ 9,936
5 lots 1,000 HK$ 12,420
6 lots 1,200 HK$ 14,904
7 lots 1,400 HK$ 17,388
8 lots 1,600 HK$ 19,872
9 lots 1,800 HK$ 22,356
10 lots 2,000 HK$ 24,840
15 lots 3,000 HK$ 37,260
20 lots 4,000 HK$ 49,680
25 lots 5,000 HK$ 62,100
30 lots 6,000 HK$ 74,520
35 lots 7,000 HK$ 86,940
40 lots 8,000 HK$ 99,360
45 lots 9,000 HK$ 111,780
50 lots 10,000 HK$ 124,200
100 lots 20,000 HK$ 248,400
150 lots 30,000 HK$ 372,600
200 lots 40,000 HK$ 496,800
250 lots 50,000 HK$ 621,000
300 lots 60,000 HK$ 745,200
350 lots 70,000 HK$ 869,400
400 lots 80,000 HK$ 993,600
450 lots 90,000 HK$ 1,117,800
500 lots 100,000 HK$ 1,242,000
750 lots 150,000 HK$ 1,863,000
1,000 lots 200,000 HK$ 2,484,000
1,250 lots 250,000 HK$ 3,105,000
1,500 lots 300,000 HK$ 3,726,000
1,750 lots 350,000 HK$ 4,347,000
2,000 lots 400,000 HK$ 4,968,000
Pool B
Lots SubscribedShares SubscribedSubscription Amount (HKD)
2,250 lots 450,000 HK$ 5,589,000
2,500 lots 500,000 HK$ 6,210,000
3,000 lots 600,000 HK$ 7,452,000
3,500 lots 700,000 HK$ 8,694,000
4,000 lots 800,000 HK$ 9,936,000
4,500 lots 900,000 HK$ 11,178,000
5,000 lots 1,000,000 HK$ 12,420,000
7,500 lots 1,500,000 HK$ 18,630,000
10,000 lots 2,000,000 HK$ 24,840,000
11,350 lots 2,270,000 HK$ 28,193,400

Stock Connect Inclusion Analysis

26Q4 Regular Review
Inclusion Pathway None
HK Market Cap ---
Est. Threshold ---
Analysis Result 无法确定入通路径

Valuation & Financials

Market Cap (at Offer Price)To be extracted
Pre-IPO Valuation (Last Round)Not disclosed
P/E RatioNot disclosed
Profit/Loss StatusTo be extracted
Period-End Cash BalanceTo be extracted
Listing ExpensesTo be extracted
Listing Expenses / Funds RaisedTo be extracted
Total Pre-IPO InvestmentTo be extracted
First Day CloseHK$ 7.65
First Day OpenHK$ 7.5
First Day Change-38.41%
First Day Volume28954400.0
First Day Turnover246224000.0
Use of Proceeds
1、約40.0%(或187.3百萬港元)將分配至戰略性重點治療領域的選定在研產品的持續研發; 2、約30.0%(或140.4百萬港元)將用于現有及接近商業化產品的營銷及商業化; 3、約10.0%(或46.8百萬港元)將用于尋求戰略合作,以豐富在目標治療領域的產品組合; 4、約10.0%(或46.8百萬港元)將用于制造系統,以建設新生產線,并升級及進一步自動化現有生產設施,從而為產品的潛在需求增長及新產品的推出做好準備; 5、約10.0%(或46.8百萬港元)將用于為營運資金及其他一般企業用途提供資金。

Underwriting Syndicate

Sole Sponsor (1)
HUATAI FINANCIAL HOLDINGS (HONG KONG) LIMITED CE AOK809
Overall Coordinators (2)
HUATAI FINANCIAL HOLDINGS (HONG KONG) LIMITED CE AOK809 CLSA LIMITED CE AAB893
Joint Bookrunners (5)
HUATAI FINANCIAL HOLDINGS (HONG KONG) LIMITED CE AOK809 CLSA LIMITED CE AAB893 招银国际融资有限公司 CE AVM940 Ruibang Securities Limited CE BIJ312 PATRONS SECURITIES LIMITED CE BPQ161
Joint Lead Managers (5)
HUATAI FINANCIAL HOLDINGS (HONG KONG) LIMITED CE AOK809 CLSA LIMITED CE AAB893 招银国际融资有限公司 CE AVM940 Ruibang Securities Limited CE BIJ312 PATRONS SECURITIES LIMITED CE BPQ161

Cornerstone Investors

#Investor NameInvestment AmountShares Subscribed% of Offer Shares% of Total SharesLock-up PeriodEst. Unlock Date
1 Alibaba Health (Hong Kong) Technology Company Limited 18,480,960 HKD — 3.28% — 6 months 2025-05-28
2 Delta Capital Hong Kong Limited 9,598,176 HKD — 1.70% — 6 months 2025-05-28
3 Jointown International Group Company Limited 18,667,260 HKD — 3.31% — 6 months 2025-05-28
4 复星实业(香港)有限公司 31,112,100 HKD — 5.52% — 6 months 2025-05-28
5 和达金源(香港)有限公司 154,012,968 HKD — 27.31% — 6 months 2025-05-28
6 吴启元 17,005,464 HKD — 3.02% — 6 months 2025-05-28
7 香港健友实业有限公司 31,112,100 HKD — 5.52% — 6 months 2025-05-28

Directors & Management

PositionChinese nameEnglish Name
Chairman傅航—
Company Secretary黃秀,何詠雅—
No director data available.

Major Shareholders

Major Shareholders & Holdings杭州中華東制藥有限公司(17.16%),杭州華升醫藥集團有限公司(13.24%),Corporacion Quimico-farmaceutica Esteve,Sociedad Anonima(12.22%),浙江網新科技創投有限公司(9.99%),Highland Pharma Limited(8.15%)
AI AI Analysis AI interpretation deepseek-v4-pro · AI-generated
!
Underlying data failed quality checks; AI interpretation downgraded and shown for reference only.

Market Sentiment

九源基因 IPO attracted overwhelming investor interest, evidenced by an oversubscription ratio of 675.83, one of the highest in recent listings. The data indicates zero accepted applications among 30,759 valid submissions, reflecting an effective zero allocation rate and extreme share scarcity. This fervent demand suggests strong market confidence despite the HK$12.42 offer price. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.)

Tier Analysis

Allocation patterns show a distinct anomaly: both 甲尾 (last A-tier) at 400,000 shares and 乙头 (first B-tier) at 450,000 shares received only 1 expected lot, neutralizing any tier advantage. This means larger applications with higher broker fees gained no extra benefit, highlighting cost inefficiency especially for those just entering the B-tier. The narrow gap between tiers amplifies this effect. (This is AI-generated commentary based on historical data. Broker fee structures vary and actual costs may differ. Not financial advice.)

Demographics

Provided demographic data is incomplete, with total holders, mainland China, and Hong Kong participation rates all recorded as zero, likely due to reporting gaps. Typically, high-demand IPOs see significant mainland participation, but no conclusions can be drawn without verified data. Investors should consult official HKEX filings for accurate distribution details. (This is AI-generated commentary based on historical data. Data may contain errors or omissions — verify against official HKEX filings. Not financial advice.)

About this page

This page shows Jiuyuan Gene (02566) prospectus details: offer price range, fundraise size, cornerstone investors, greenshoe, Pool A/B allocation and syndicate. For eligible IPOs it also provides a Stock Connect inclusion analysis, indicating the pathway and estimated timing for Southbound Connect admission; for A-share / US secondary listings, it additionally compares the other market's price, exchange rate and the H-share premium/discount. Data is parsed from the HKEX prospectus and related announcements. New to IPO subscription? See Hong Kong IPO Subscription 101.

Cibo — HK IPO Allotment Forecasts, Allottee Profiling & Stock Connect